Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics

References

• Venkatraman SS, Ma LL, Natarajan JV, et al. Polymer- and liposome-based nanoparticles in targeted drug delivery. Front Biosci (Schol Ed). 2010;2:801–814.
   PubMedGoogle Scholar
• De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3:133–149.
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148:135–146.
   PubMed Web of Science ®Google Scholar
• Ehrlich P. The collected papers of Paul Ehrlich. London: Pergamon; 1960. p. 3.
   Google Scholar
• Dancey JE. Recent advances of molecular targeted agents: opportunities for imaging. Cancer Biol Ther. 2003;2:601–609.
   PubMed Web of Science ®Google Scholar
• James ND, Coker RJ, Tomlinson D, et al. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. Clin Oncol (R Coll Radiol). 1994;6:294–306.
   PubMedGoogle Scholar
• Hofheinz RD, Gnad-Vogt SU, Beyer U, et al. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs. 2005;16:691–707.
   PubMed Web of Science ®Google Scholar
• WHO. Ultraviolet radiation. Skin cancers. 2016. Available from: www.who.int/uv/faq/skincancer/en/index1.html
   Google Scholar
• Markman JL, Rekechenetskiy A, Holler E, et al. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev. 2013;65:1866–1879.
   PubMed Web of Science ®Google Scholar
• Hua S. Lipid-based nano-delivery systems for skin delivery of drugs and bioactives. Front Pharmacol. 2015;6:1–5.
   PubMed Web of Science ®Google Scholar
• Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 2013;48:416–427.
   PubMed Web of Science ®Google Scholar
• Cancer Quest. 2016. Available from: https://www.cancerquest.org/cancer-biology/angiogenesis?gclid
   Google Scholar
• Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. Biodrugs. 2009;23:289–304.
   PubMed Web of Science ®Google Scholar
• Jain V, Jain S, Mahajan SC. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment. Curr Drug Deliv. 2015;12:177–191.
   PubMed Web of Science ®Google Scholar
• Medina OP, Ying Z, Kalevi K. Targeted liposomal drug delivery in cancer. Curr Pharm Des. 2004;10:2981–2989.
   PubMed Web of Science ®Google Scholar
• Kanapathipillai M, Brock A, Ingber DE. Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment. Adv Drug Deliv Rev. 2014;15:107–118.
   Google Scholar
• Mukherjee B, Satapathy BS, Mondal L, et al. Potentials and challenges of active targeting at the tumor cells by engineered polymeric nanoparticles. Curr Pharm Biotechnol. 2013;14:1250–1263.
   PubMed Web of Science ®Google Scholar
• Zorko M, Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev. 2005;57:529–545.
   PubMed Web of Science ®Google Scholar
• Xu S, Olenyuk BZ, Curtis T, et al. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev. 2013;65:121–138.
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732–6740.
   PubMed Web of Science ®Google Scholar
• Asghari F, Samiei M, Adibkia K, et al. Biodegradable and biocompatible polymers for tissue engineering application: a review. Artif Cells Nanomed Biotechnol. 2016;45:185–192.
   PubMed Web of Science ®Google Scholar
• Pastorino FC, Brignole PD, Di B, et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature specific ligands potentiates therapeutic efficacy. Cancer Res. 2006;66:10073–10082.
   PubMed Web of Science ®Google Scholar
• Daniels TR, Delgado T, Helguera G, et al. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006;121:159–176.
   PubMed Web of Science ®Google Scholar
• Choi CH, Alabi CA, Webster P, et al. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA. 2010;107:1235–1240.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan W, Dai X, et al. Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles. Mol Pharm. 2014;11:1140–1150.
   PubMed Web of Science ®Google Scholar
• Muthu MS, Kutty RV, Luo Z, et al. Theranostic vitamin E TPGS micelles of transferrin conjugation for targeted co-delivery of docetaxel and ultra bright gold nanoclusters. Biomaterials. 2015;39:234–248.
   PubMed Web of Science ®Google Scholar
• Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009;13:256–262.
   PubMed Web of Science ®Google Scholar
• Wu W, Zheng Y, Wang R, et al. Antitumor activity of folate-targeted paclitaxel-loaded polymeric micelles on a human esophageal EC9706 cancer cell line. Int J Nanomed. 2012;7:3487–3502.
   PubMed Web of Science ®Google Scholar
• Platt VM, Szoka FC, Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm. 2008;5:474–486.
   PubMed Web of Science ®Google Scholar
• Qhattal HSS, Liu X. Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol Pharm. 2011;8:1233–1246.
   PubMed Web of Science ®Google Scholar
• Yanhua L, Chengming Z, Wenping W, et al. CD44 receptor targeting and endosomal pH-sensitive dual functional hyaluronic acid micelles for intracellular paclitaxel delivery. Mol Pharm. 2016;13:4209–4221.
   PubMedGoogle Scholar
• Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer. 2005;5:436–446.
   PubMed Web of Science ®Google Scholar
• Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69:4–10.
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.
   PubMed Web of Science ®Google Scholar
• Dienst A, Grunow A, Unruh M, et al. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J Natl Cancer Inst. 2005;97:733–747.
   PubMed Web of Science ®Google Scholar
• Genis L, Galvez BG, Gonzalo P, et al. MT1-MMP: universal or particular player in angiogenesis? Cancer Metastasis Rev. 2006;25:77–86.
   PubMed Web of Science ®Google Scholar
• Hembram KC, Prabha S, Chandra R, et al. Advances in preparation and characterization of chitosan nanoparticles for therapeutics. Artif Cells Nanomed Biotechnol. 2014;44:305–314.
   PubMed Web of Science ®Google Scholar
• Ebrahimi E, Akbarzadeh A, Abbasi E, et al. Novel drug delivery system based on doxorubicin encapsulated magnetic nanoparticles modified with PLGA-PEG1000 copolymer. Artif Cells Nanomed Biotechnol. 2016;44:290–297.
   PubMed Web of Science ®Google Scholar
• Miele E, Spinelli GP, Tomao F, et al. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomed. 2009;4:99–105.
   PubMed Web of Science ®Google Scholar
• Lin C-H, Chenga S-H, Liaoa W-N, et al. Mesoporous silica nanoparticles for the improved anticancer efficacy of cisplatin. Int J Pharm. 2012;429:138–147.
   PubMed Web of Science ®Google Scholar
• Punjabi A, Wu X, Tokatli-Apollon A, et al. Amplifying the red-emission of upconverting nanoparticles for biocompatible clinically used prodrug-induced photodynamic therapy. ACS Nano. 2014;8:10621–10630.
   PubMed Web of Science ®Google Scholar
• Gosk S, Moos T, Gottstein C, et al. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta. 2008;1778:854–863.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang M, Zhang N, et al. Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes. Int J Nanomed. 2011;6:2641–2652.
   PubMed Web of Science ®Google Scholar
• Jin Y, Zhang Z, Zhao T, et al. Mixed micelles of doxorubicin overcome multidrug resistance by inhibiting the expression of P-glycoprotein. J Biomed Nanotechnol. 2015;11:1330–1338.
   PubMed Web of Science ®Google Scholar
• Alakhova DY, Zhao Y, Li S, et al. Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia. PLoS One. 2013;8:e72238.
   PubMed Web of Science ®Google Scholar
• Lee JY, Chung SJ, Cho HJ, et al. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery. Eur J Pharm Biopharm. 2015;94:532–541.
   PubMed Web of Science ®Google Scholar
• Roy K, Kanwar RK, Kanwar JR. LNA aptamer based multi-modal Fe3O4- saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM CD133 CD44) colon tumor targeting and NIR MRI and CT imaging. Biomaterials. 2015;71:84–99.
   PubMed Web of Science ®Google Scholar
• Shah V, Taratula O, Garbuzenko OB, et al. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res. 2013;9:6193–6204.
   Web of Science ®Google Scholar
• Andre ND, Silva VA, Ariza CB, et al. In vivo knockdown of CXCR4 using jetPEI/CXCR4 shRNA nanoparticles inhibits the pulmonary metastatic potential of B16-F10 melanoma cells. Mol Med Rep. 2015;12:8320–8326.
   PubMed Web of Science ®Google Scholar
• Ni M, Xiong M, Zhang X, et al. Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells. Int J Nanomed. 2015;10:2537–2554.
   PubMed Web of Science ®Google Scholar
• Wang H, Yin H, Yan F, et al. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance. Oncotarget. 2015;6:2827–2842.
   PubMed Web of Science ®Google Scholar
• Kim J-H, Kim Y-S, Park K, et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release. 2008;127:41–49.
   PubMed Web of Science ®Google Scholar
• Acharya S, Dilnawaz F, Sahoo SK. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials. 2009;30:5737–5750.
   PubMed Web of Science ®Google Scholar
• Nasab NA, Kumleh HH, Beygzadeh M, et al. Delivery of curcumin by a pH-responsive chitosan mesoporous silica nanoparticles for cancer treatment. Artif Cells Nanomed Biotechnol. Forthcoming. [cited 2017 Feb 23]. DOI:10.1080/21691401.2017.1290648
   Web of Science ®Google Scholar
• Liberman A, Mendez N, Trogler WC, et al. Synthesis and surface functionalization of silica nanoparticles for nanomedicine. Surf Sci Rep. 2014;69:132–158.
   PubMed Web of Science ®Google Scholar
• Deng Z, Zhen Z, Hu X, et al. Hollow chitosan-silica nanospheres as pH-sensitive targeted delivery carriers in breast cancer therapy. Biomaterials. 2011;32:4976–4986.
   PubMed Web of Science ®Google Scholar
• Luo D, Saltzman WM. Enhancement of transfection by physical concentration of DNA at the cell surface. Nat Biotechnol. 2000;18:893–895.
   PubMed Web of Science ®Google Scholar
• Mohammadi Z, Sazgarnia A, Rajabi O, et al. Comparative study of X-ray treatment and photodynamic therapy by using 5-aminolevulinic acid conjugated gold nanoparticles in a melanoma cell line. Artif Cells Nanomed Biotechnol. 2017;45:467–473.
   PubMed Web of Science ®Google Scholar
• Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Crit Rev Ther Drug Carrier Syst. 2003;20:357–403.
   PubMed Web of Science ®Google Scholar
• Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub- 100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6:815–823.
   PubMed Web of Science ®Google Scholar
• Haussecker D. The business of RNAi therapeutics in 2012. Mol Ther Nucleic Acids. 2012;1:e8.
   PubMedGoogle Scholar
• Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev. 2008;60:1037–1055.
   PubMed Web of Science ®Google Scholar
• Lee CC, MacKay JA, Frechet JMJ, et al. Designing dendrimers for biological applications. Nat Biotechnol. 2005;23:1517–1526.
   PubMed Web of Science ®Google Scholar
• The Economic Times. 2016. Available from: http://economictimes.indiatimes.com/articleshow/55974699.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
   Google Scholar
• Sinha N, Yeow JTW. Carbon nanotubes for biomedical applications. IEEE Trans Nanobiosci. 2005;4:180–195.
   PubMed Web of Science ®Google Scholar
• Fabbro C, Ali-Boucetta H, Da Ros T, et al. Targeting carbon nanotubes against cancer. Chem Commun (Camb). 2012;48:3911–3926.
   PubMed Web of Science ®Google Scholar
• Bhirde AA, Patel V, Gavard J, et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano. 2009;3:307–316.
   PubMed Web of Science ®Google Scholar
• Liu Z, Tabakman S, Welsher K, et al. Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery. Nano Res. 2009;2:85–120.
   PubMed Web of Science ®Google Scholar
• Ali-Boucetta H, Al-Jamal KT, McCarthy D, et al. Multiwalled carbon nanotube–doxorubicin supramolecular complexes for cancer therapeutics. Chem Commun. 2008;4:459–461.
   PubMed Web of Science ®Google Scholar
• Datir SR, Das M, Singh RP, et al. Hyaluronate tethered, “smart” multiwalled carbon nanotubes for tumor-targeted delivery of doxorubicin. Bioconjug Chem. 2012;23:2201–2213.
   PubMed Web of Science ®Google Scholar
• Ren J, Shen S, Wang D, et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials. 2012;33:3324–3333.
   PubMed Web of Science ®Google Scholar
• Singh R, Mehra NK, Jain V, et al. Gemcitabine-loaded smart carbon nanotubes for effective targeting to cancer cells. J Drug Target. 2013;21:581–592.
   PubMed Web of Science ®Google Scholar
• Abbasi E, Akbarzadeh A, Kouhi M, et al. Graphene: synthesis, bio-applications, and properties. Artif Cells Nanomed Biotechnol. 2016;44:150–156.
   PubMed Web of Science ®Google Scholar
• Jung HS, Kong WH, Sung DK, et al. Nanographene oxide-hyaluronic acid conjugate for photothermal ablation therapy of skin cancer. ACS Nano. 2014;8:260–268.
   PubMed Web of Science ®Google Scholar
• Wei Y, Zhou F, Zhang D, et al. A graphene oxide based smart drug delivery system for tumor mitochondria-targeting photodynamic therapy. Nanoscale. 2016;8:3530–3538.
   PubMed Web of Science ®Google Scholar
• Yang X, Wang Y, Huang X, et al. Multi- functionalized graphene oxide based anticancer drug-carrier with dual-targeting function and pH- sensitivity. J Mater Chem. 2011;21:3448–3454.
   Web of Science ®Google Scholar
• Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol. 2014;44:27–40.
   PubMed Web of Science ®Google Scholar
• Adabi M, Naghibzadeh M, Adabi M, et al. Biocompatibility and nanostructured materials: applications in nanomedicine. Artif Cells Nanomed Biotechnol. 2017;45:833–842.
   PubMed Web of Science ®Google Scholar
• Aberoumandi SM, Mohammadhosseini M, Abasi E, et al. An update on applications of nanostructured drug delivery systems in cancer therapy: a review. Artif Cells Nanomed Biotechnol. 2016;45:1–1068.
   PubMed Web of Science ®Google Scholar
• Shao Z, Shao J, Tan B, et al. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int J Nanomed. 2015;10:1223–1233.
   PubMed Web of Science ®Google Scholar
• Rajinikanth PS, Chellian J. Development and evaluation of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil. Int J Nanomed. 2016;11:5067–5077.
   PubMed Web of Science ®Google Scholar
• Koopaei MN, Dinarvand R, Amini M, et al. Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation characterization and cytotoxicity studies. Int J Nanomed. 2011;6:1903–1912.
   PubMed Web of Science ®Google Scholar
• Bourseau-Guilmaina E, Bejauda J, Griveaua A, et al. Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133. Int J Pharm. 2012;423:93–101.
   PubMedGoogle Scholar
• In-Pharma Technologist.com. 2016. Available from: http://www.in-pharmatechnologist.com/Drug-Delivery/Gold-nanoshells-may-offer-new-delivery-option-for-cancer-hypothermia-drugs
   Google Scholar
• Liang Z, Li X, Xie Y, et al. “Smart” gold nanoshells for combined cancer chemotherapy and hyperthermia. Biomed Mater. 2014;9:025012.
   PubMed Web of Science ®Google Scholar
• Zhao N, You J, Zeng Z, et al. An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. Small. 2013;9:3477–3484.
   PubMed Web of Science ®Google Scholar
• Pondman KM, Bunt ND, Maijenburg AW, et al. Magnetic drug delivery with FePd nanowires. J Magn Magn Mater. 2015;380:299–306.
   Web of Science ®Google Scholar
• Peng F, Su Y, Wei X, et al. Silicon-nanowire-based nanocarriers with ultrahigh drug-loading capacity for in vitro and in vivo cancer therapy. Angew Chem Int Ed Engl. 2013;52:1457–1461.
   PubMed Web of Science ®Google Scholar
• Li K-C, Chu H-C, Lin Y, et al. PEGylated copper nanowires as a novel photothermal therapy agent. ACS Appl Mater Interfaces. 2016;8:12082–12090.
   PubMed Web of Science ®Google Scholar